Last reviewed 2026-04-20 · How we verify

Plegridy

At a glance

Approved indications

• Relapsing remitting multiple sclerosis

Common side effects

• Influenza-like illness
• Headache
• Chills
• Injection site erythema
• Injection site pain
• Pain
• Myalgia
• Pyrexia
• Asthenia
• Injection site pruritus
• Arthralgia

Key clinical trials

• An Observational Study to Learn About the Interferon-beta Exposure of Pregnant Women During the Second and Third Trimester in Finland and Sweden
• A Study to Learn More About The Safety of Diroximel Fumarate (VUMERITY®) in Participants Who Took it During Pregnancy And About the Health of Their Babies
• Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial (NA)
• A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis (PHASE3)
• Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS (PHASE4)
• Pharmacodynamic Biomarkers to Support Biosimilar Development: Interferon Beta-1A Products (PHASE1)
• Plegridy Satisfaction Study in Participants (PHASE4)
• Human Intravenous Interferon Beta-Ia Safety and Preliminary Efficacy in Hospitalized Subjects With COVID-19 (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Plegridy CI brief — competitive landscape report
• Plegridy updates RSS · CI watch RSS
• Holy Name Medical Center, Inc. portfolio CI